LEADER 05110nam 2200613 450 001 9910144111403321 005 20170816115845.0 010 $a1-281-94674-5 010 $a9786611946746 010 $a3-527-62215-2 010 $a3-527-62216-0 035 $a(CKB)1000000000556381 035 $a(EBL)481597 035 $a(OCoLC)277256521 035 $a(SSID)ssj0000123683 035 $a(PQKBManifestationID)11134814 035 $a(PQKBTitleCode)TC0000123683 035 $a(PQKBWorkID)10011716 035 $a(PQKB)11110254 035 $a(MiAaPQ)EBC481597 035 $a(EXLCZ)991000000000556381 100 $a20160818h20082008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aClinical proteomics $efrom diagnosis to therapy /$fedited by Jennifer E. Van Eyk and Michael J. Dunn 210 1$aWeinheim, [Germany] :$cWiley-VCH Verlag GmbH & Co. KGaA,$d2008. 210 4$dİ2008 215 $a1 online resource (695 p.) 300 $aIncludes index. 311 $a3-527-31637-X 327 $aClinical Proteomics; Contents; Editor's Overview; Acknowledgements; List of Contributors; I Technologies; 1 Preanalytical Issues in Clinical Proteomic Studies; 1.1 Introduction; 1.2 Preanalytical Factors; 1.2.1 Biological Variation; 1.2.1.1 Intrinic Influences/Factors; 1.2.1.2 Extrinsic Influences/Factors; 1.2.2 Technical Variables; 1.2.2.1 Specimen/Sample Collection Mode; 1.2.2.2 Type of Sample Container; 1.2.2.3 Sample Processing and Handling Conditions; 1.2.2.4 Sample Storage; 1.3 Summary and Concluding Remarks; 2 Protein Separation by Two-Dimensional Electrophoresis; 2.1 Introduction 327 $a2.2 2DE: Protein Solubilization and Sample Preparation2.3 2DE: Protein Separation; 2.3.1 Focusing in the First Dimension; 2.3.2 Advances in IEF; 2.4 Improving Proteomic Coverage by Subcellular Fractionation; 2.5 Protein Detection and Image Analysis; 2.6 The Future of 2DE; 3 Protein Separation: Liquid Chromatography; 3.1 Introduction; 3.2 Liquid Chromatography; 3.2.1 HPLC Separation Principles; 3.2.2 Reversed-Phase LC (RPLC, 1DLC); 3.2.3 Affinity Chromatography; 3.2.4 Size-Exclusion Chromatography; 3.2.5 Ion-Exchange Chromatography; 3.2.6 Two-Dimensional LC 327 $a3.2.6.1 Chromatofocusing to Reversed Phase3.2.6.2 Ion-Exchange-Reversed-Phase Liquid Chromatography; 3.2.7 Three-Dimensional Liquid Chromatography; 3.2.8 LC Image Analysis Requirement; 3.2.9 Mass Spectrometry for LC; 3.2.9.1 MALDI-TOF MS; 3.2.9.2 ESI-MS/MS; 3.3 Conclusions; 4 HPLC in Protein Discovery; 4.1 Introduction; 4.2 LC-Based Approaches in Peptide Mass Mapping; 4.3 LC-Based Approaches in Protein Mapping; 4.4 Orthogonal 2D HPLC Separations; 4.5 Conclusion; 5 IEF Analysis of Peptides for Biomarkers Discovery; 5.1 Introduction; 5.2 Background; 5.2.1 Isoelectric Focusing 327 $a5.2.2 Shotgun Proteomics5.2.3 Shotgun IEF; 5.3 Shotgun IEF Workflow; 5.4 Applications; 5.5 Discussion and Outlook; 6 Capillary Electrophoretic Separations for Clinical Proteomics; 6.1 Introduction; 6.2 (Single-Dimension) Capillary Electophoretic Separation; 6.3 Capillary Electrophoresis-Based Multidimensional Separations; 6.3.1 Capillary Liquid Chromatography-Capillary Electrophoresis; 6.3.2 Capillary Electrophoresis-Capillary Electrophoresis; 6.3.3 Capillary Electrophoresis-Liquid Chromatography; 6.3.3.1 Characterization of Human Saliva Proteome; 6.3.3.2 Targeted Tissue Proteomics 327 $a6.4 Conclusions7 Quantitative Proteomics Using Nano-LC with High Accuracy Mass Spectrometry; 7.1 Introduction; 7.2 Fundamentals of a High Mass Accuracy-Based LC-MS Approach; 7.3 Nano-LC-MS for Enhanced Sensitivity and Dynamic Range Coverage; 7.4 Further Developments for Increasing Proteomic Throughput; 7.5 Obtaining More Robust Quantitative Proteomic Measurements; 7.6 Summary and Perspective; 8 Antibody Microarrays for Protein and Glycan Detection; 8.1 Introduction; 8.2 Antibody Preparation and Microarray Production; 8.3 Sandwich Assays with Fluorescence Detection 327 $a8.4 Antibody Microarrays with Lectin Detection 330 $aUnparalleled in its scope and depth, this book brings together proteomic approaches in diagnosis and treatment from all clinical fields, including clinical toxicology. The result is a new discipline in molecular medicine that will revolutionize the treatment and prevention of cancer, stroke and other severe diseases.Following an overview of clinical proteomics, the authors look at the technologies available, before moving on to cancer, cardiopulmonary disease, diabetes and stroke. A whole section is devoted to toxicity and the work is rounded off with a discussion of the future of clinical 606 $aProteomics 608 $aElectronic books. 615 0$aProteomics. 676 $a572.6 676 $a612.015 702 $aVan Eyk$b Jennifer E. 702 $aDunn$b Michael J. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910144111403321 996 $aClinical proteomics$91012069 997 $aUNINA